RxDoctor Payments Data

Larissa Fujii-Lau, MD

Internal Medicine · Rochester, MNNPI 1518127919

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (43.8%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 77.5% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $12,303 and has fallen 74.9% since, to $3,091 in 2025. Among internal medicine clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$21,711in general payments, 2019–2025

Across 146 payments — averaging $148.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$17K
  • Cook Medical LLC$2K
  • AbbVie$1K
  • Johnson & Johnson$218
  • Takeda Pharmaceuticals U.S.A., Inc.$180
  • Conmed Corporation$165
  • plus $853 from 12 others

What the payments were for

  • Speaking & faculty fees$9,50044%
  • Grants$2,09210%
  • Travel & lodging$5,75026%
  • Food & beverage$4,29320%
  • Education$770%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,711 in reported general payments places this provider in the 95th percentile of 1,924 internal medicine providers in Minnesota.

See all internal medicine providers in Minnesota

Medicare billing

Part B allowed, 2024
$116,761
Medicare patients
427
Services billed
1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase39$77,285
LinzessLinaclotide16$11,309
Omeprazole234$5,366
DexilantDexlansoprazole11$3,482
Pantoprazole Sodium85$1,888
Famotidine29$765
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg27$544
Sucralfate14$544
Dicyclomine Hcl17$196
Ciprofloxacin Hcl41$131
Metronidazole12$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,383$88,59455 claims
Takeda Pharmaceuticals U.S.A., Inc.Dexilant$180$3,48211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,924 internal medicine providers in Minnesota.

Other internal medicine in Rochester

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →